REVISTA BIOMÉDICA REVISADA POR PARES

Revisión clínica

Revisión clínica

Medwave 2013;13(3):e5657 doi: 10.5867/medwave.2013.03.5657

Insulinorresistencia y generación de productos finales de la glucosilación avanzada

Insulin resistance and generation of advanced glycation end products

  1. Tamaño letra: (A+)  (A-)
  2. Descargar PDF.
  3. Recomendar este artículo.
  4. Lectura fácil.
  5. Compartir este artículo en:
     

     

     

Citación: Gudiño A, Chediak MC. Insulin resistance and generation of advanced glycation end products. Medwave 2013;13(3):e5657 doi: 10.5867/medwave.2013.03.5657
Fecha de envío: 3/2/2013
Fecha de aceptación: 26/3/2013
Fecha de publicación: 16/4/2013
Origen: no solicitado
Tipo de revisión: con revisión externa por dos pares revisores, a doble ciego

Citaciones asociadas

Masthead April 2013. Medwave 2013 Abr;13(3):e5648 | Link |


Autores: Alvaro Gudiño Gomezjurado(1), María Cristina Chediak Terán(2)
Filiación:
(1)Médico Internista, Pontificia Universidad Católica del Ecuador, Quito, Ecuador
(2)Médico General, Hospital de Yaruqui, Quito, Ecuador
E-mail: alvaro1983@outlook.com
Correspondencia a: [+]

(1)Av. 12 de Octubre
Quito, Cantón Quito,
Pichincha, Ecuador
(X) Cerrar Correspondencia

Resumen [+] Abstract [+]

Resumen

La diabetes mellitus tipo 2 constituye una de las enfermedades más comúnmente diagnosticadas y a largo plazo lleva a diferentes complicaciones. Uno de los mecanismos por el cual se desarrollan estas alteraciones es la insulinorresistencia que impide que la glucosa sea utilizada por los diferentes órganos y tejidos, determinando alteraciones estructurales y funcionales a nivel celular. Dentro de este espectro la formación de los productos finales de la glucosilación avanzada ha alcanzado singular importancia, ya que han sido implicados en varios procesos degenerativos. Ello vuelve imperativa la necesidad de investigar potenciales blancos terapéuticos que permitan mejorar el pronóstico y la calidad de vida de los pacientes afectados por estas enfermedades.
(X) Cerrar Resumen

Abstract

Diabetes mellitus type 2 is one of the most frequently diagnosed diseases and in the long-term leads to a variety of complications. One of the mechanisms involved in these effects is insulin resistance which prevents glucose from being used by the different target organs and tissues, which in turn leads to structural and functional changes at the cellular level. In this context, the formation of advanced glycation end products has attained special importance as they have been implicated in several degenerative processes. It thus becomes necessary to look into potential therapeutic targets with the purpose of improving prognosis and quality of life of patients suffering from these diseases.
(X) Close Abstract

Palabras clave: insulin resistance, advanced glycation end products, receptor for advanced glycation end products (RAGE)

Abreviaturas:
DM: Diabetes mellitus
AGE: Advanced Glycation End products
RAGE: Receptor for Advanced Glycation End products
GLUT-1: Transportadores de Glucosa tipo 1
GLUT-2: Transportadores de Glucosa tipo 2
GLUT-4: Transportadores de Glucosa tipo 4
IGF-1: Insulin-like Growth Factor 1
IL-1: Interleukin 1
IL-6: Interleukin 6
IL-18: Interleukin 18
NADPH oxidasa: nicotinamida adenina dinucleótido fosfato-oxidasa
TNF-α: Tumoral Necrosis Factor alpha
PCR: proteína C reactiva
RBP-4: Retinol Binding Protein 4
HbA1C: Hemoglobina glucosilada A1C

Referencias

  1. American Diabetes Association .Position Statement: American Diabetes AssociationDiagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2012 Jan;35(1):64-71. | CrossRef | PubMed |
  2. Wong ND, Sciammarella MG, Polk D, Gallagher A, Miranda-Peats L, Whitcomb B, et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol. 2003 May; 41(9):1547-53. | PubMed |
  3. Basha B, Samuel SM, Triggle CR, Ding H. Endothelial dysfunction in diabetes mellitus : possible involvement of endoplasmic reticulum stress? Exp Diabetes Res. 2012;(2012):1-14. | CrossRef | PubMed | PMC |
  4. Kishore P, Kim SH, Crandall JP. Glycemic control and cardiovascular disease: what's a doctor to do? Curr Diab Rep. 2012 Jun;12(3):255-64. | CrossRef | PubMed | PMC |
  5. Gong Z, Muzumdar RH. Pancreatic function, type 2 diabetes, and metabolism in aging. Int J Endocrinol. 2012; (2012):1-13. | CrossRef | PubMed | PMC |
  6. Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell. 2012 Mar;148(6):1160-71. | CrossRef | PubMed |
  7. Gallagher EJ, Leroith D, Karnieli E. The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am. 2008 Sep;95(5):855-73. | CrossRef | PubMed |
  8. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus . Med Clin North Am. 2004 Jul;88(4):787-835. | CrossRef | PubMed |
  9. Cho LW. Metabolic syndrome. Singapore Med J. 2011 Nov;52(11):779-785. | PubMed |
  10. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes. 2004 Dec; 53( 3):34-38. | CrossRef | PubMed |
  11. Faerch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009 Sep;52(9):1714-23. | CrossRef | PubMed |
  12. Ismail-Beigi F. Pathogenesis and glycemic management of type 2 diabetes mellitus: a physiological approach. Arch Iran Med. 2012 Apr;15(4):239-46. | CrossRef | PubMed |
  13. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000 Dec;1498(2-3):99-111. | CrossRef | PubMed |
  14. Badaru A, Pihoker C. Type 2 diabetes in childhood: clinical characteristics and role of β-cell autoimmunity. Curr Diab Rep. 2012 Feb;12(1):75-81 | CrossRef | PubMed |
  15. Franks PW. Gene × environment interactions in type 2 diabetes. Curr Diab Rep. 2011 Dec;11(6):552-61. | CrossRef | PubMed |
  16. Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol. 2012;(2012):1-18. | CrossRef | PubMed | PMC |
  17. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002 Apr;23(2):201-29. | CrossRef | PubMed |
  18. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):3-14. | CrossRef | PubMed |
  19. Vrachnis N, Augoulea A, Iliodromiti Z, Lambrinoudaki I, Sifakis S, Creatsas G. Previous gestational diabetes mellitus and markers of cardiovascular risk. Int J Endocrinol. 2012;(2012):1-6. | CrossRef | PubMed | PMC |
  20. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011 Sep;60(9):2379-2385. | CrossRef | PubMed | PMC |
  21. Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012 Mar;366(13):1209-17. | CrossRef |
  22. Ren J, Ceylan-Isik AF. Diabetic cardiomyopathy: do women differ from men? Endocrine. 2004 Nov;25(2):73-83. | CrossRef | PubMed |
  23. Sinclair A, Viljoen A. The metabolic syndrome in older persons. Clin Geriatr Med. 2010 May;26(2):261-74. | CrossRef |
  24. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond). 2011 Jul;121(2):43-55. | CrossRef | PubMed |
  25. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parvings HH, et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes Care. 2011 Feb;34(2):442-47. | CrossRef | PubMed | PMC |
  26. Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012 Apr;4(4):90-102. | CrossRef | PubMed | PMC |
  27. Song F, Schmidt AM. Glycation and insulin resistance: novel mechanisms and unique targets? Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1760-1765. | CrossRef | PubMed |
  28. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi SI, et al. Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study. Cardiovasc Diabetol. 2013 Jan 7;12(1):5. | CrossRef | PubMed | PMC |
  29. Teupe C, Rosak C. Diabetic cardiomyopathy and diastolic heart failure - Difficulties with relaxation. Diabetes Res Clin Pract. 2012 Aug; 97(2):185-94. | CrossRef | PubMed |
  30. Zakliczynski M, Nozynski J, Konecka-Mrowka D, Lange D, Zakliczynska H, Szygula-Jurkiewicz B, et al. Paradox of advanced glycation end-products in late cardiac biopsies of heart transplant recipients. Transplant Proc. 2011 Oct;43(8):3058-60. | CrossRef | PubMed |
  31. Del Turco S, Basta G. An update on advanced glycation endproducts and atherosclerosis. Biofactors. 2012 Jul;38(4):266-74. | CrossRef | PubMed |
  32. Mallipattu SK, He JC, Uribarri J. Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients. Semin Dial. 2012 Sep-Oct;25(5):529-38. | CrossRef | PubMed |
  33. Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J, et al. Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol. 2013 Feb;28(2):369-76. | CrossRef | PubMed |
  34. Moy KA, Jiao L, Freedman ND, Weinstein SJ, Sinha R, Virtamo J, Albanes D, et al. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology. 2013 Jan. | CrossRef | PubMed |
  35. Martens HA, Nienhuis HL, Gross S, van der Steege G, Brouwer E, Berden JH, et al. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus. 2012 Aug; 21(9):959-68. | CrossRef | PubMed |
  36. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res. 2011 Mar;12(1):3. | CrossRef | PubMed | PMC |
  37. Engelen L, Stehouwer, CD, Schalkwijk, CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab. 2012 Dec. | CrossRef | PubMed |
    1. Licencia Creative Commons
      Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.


       

< Volver arriba >

Villaseca 21, Of. 702, Ñuñoa, Santiago de Chile.
Fonos: 56-2-22743013 ó 56-2-23731570. Fax: 56-2-27243013.
Síganos en Twitter y en Facebook.